Researcher
Jo Van Ginderachter
- Keywords (Vrije Universiteit Brussel):Applied biological sciences, biotechnology
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Adaptive immunology, Bacteriology
- Disciplines (Vrije Universiteit Brussel):Applied immunology
Affiliations
- Cellular and Molecular Immunology (Research group)
Responsible
From1 Oct 1995 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Jan 2024 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2019 → 31 Dec 2023 - Department of Bio-engineering Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2019 - Van Ginderachter Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2012 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2010 → 20 Oct 2022 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 1999 → 30 Sep 2014
Projects
1 - 10 of 26
- Therapeutic targeting of tumor-associated macrophages with anti-CD163 Nanobody-drug conjugates as novel cancer therapyFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Blocking the immunoregulatory family members D-dopachrome tautomerase (D-DT) and Macrophage Migration Inhibitory Factor (MIF) to improve immunotherapy of cancerFrom1 Nov 2022 → TodayFunding: FWO fellowships
- SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancerFrom1 Nov 2022 → TodayFunding: BOF - projects
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → 31 Mar 2024Funding: IOF - technology validation in real environment
- SBO Project : LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
- Optimized anti-Neuropilin-1 Nanobody formats as cancer therapyFrom1 Nov 2021 → TodayFunding: FWO fellowships
- Immunological memory of the macrophage niche (MacNicheMemo).From1 Jan 2021 → TodayFunding: BOF - iBOF
- Blocking Lipocalin-2 (Lcn-2) using Nanobodies as novel cancer therapyFrom1 Nov 2020 → TodayFunding: FWO fellowships
- Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization systemFrom1 May 2020 → TodayFunding: Hercules - Small and Medium size research infrastructure
Publications
11 - 20 of 101
- Junctional adhesion molecule-A is dispensable for myeloid cell recruitment and diversification in the tumor microenvironment(2022)
Authors: Máté Kiss, Els Lebegge, Aleksandar Murgaski, Helena Van Damme, Daliya Kancheva, Jan Brughmans, Isabelle Scheyltjens, Ali Talebi, Robin Maximilian Awad, Yvon Elkrim, et al.
- Differential plasticity and fate of brain-resident and recruited macrophages during the onset and resolution of neuroinflammation(2022)
Authors: Karen De Vlaminck, Hannah Van Hove, Daliya Kancheva, Isabelle Scheyltjens, Ana Rita Pombo Antunes, Jonathan Bastos, Mónica Vara-Pérez, Leen Ali, Myrthe Mampay, Lauren Deneyer, et al.
Pages: 2085-2102 - The Heat Is On(2022)
Authors: Jo A Van Ginderachter
Pages: 3882-3883 - GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide(2022)
Authors: Sweta Parik, Juan Fernández-García, Francesca Lodi, Karen De Vlaminck, Marleen Derweduwe, Steven De Vleeschouwer, Raf Sciot, Wietse Geens, Linqian Weng, Francesca Maria Bosisio, et al.
- Enteric glial cells favor accumulation of anti-inflammatory macrophages during the resolution of muscularis inflammation(2022)
Authors: Michelle Stakenborg, Saeed Abdurahiman, Veronica De Simone, Gera Goverse, Nathalie Stakenborg, Lies van Baarle, Qin Wu, Dimitri Pirottin, Jung Seok Kim, Louise Chappell-Maor, et al.
Pages: 1296-1308 - Imaging and therapeutic targeting of the tumor immune microenvironment with biologics(2022)
Authors: Sana M Arnouk, Timo W M De Groof, Jo A Van Ginderachter
- Investigating the role of fatty acid desaturation in cancer(2022)
Authors: Sweta Parik, Jo A Van Ginderachter, Sarah-Maria Fendt
Number of pages: 138 - A combination of ontogeny and environment drives macrophage identity across brain regions(2022)
Authors: Hannah Van Hove, Kiavash Movahedi, Jo A Van Ginderachter
Number of pages: 187 - Macrophages are metabolically heterogeneous within the tumor microenvironment(2021)
Authors: Xenia Geeraerts, Juan Fernández-Garcia, Felix J. Hartmann, Kyra E. de Goede, Liesbet Martens, Yvon Elkrim, Ayla Debraekeleer, Benoît Stijlemans, Anke Vandekeere, Gianmarco Rinaldi, et al.
Pages: 110171 - Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha(2021)
Authors: Karen De Vlaminck, Ema Romão, Janik Puttemans, Ana Rita Pombo Antunes, Daliya Kancheva, Isabelle Scheyltjens, Jo A Van Ginderachter, Serge Muyldermans, Nick Devoogdt, Kiavash Movahedi, et al.
Patents
1 - 6 of 6
- Tumor-associated dendritic cell preparations and uses thereof (Inventor)
- Non-blocking human ccr8 binders (Inventor)
- Human ccr8 binders (Inventor)
- Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer (Inventor)
- Murine cross-reactive human ccr8 binders (Inventor)